Acer Medical Business Summary

Acer Medical Inc. operates as a specialized Software as a Medical Device (SaMD) provider, generating revenue through software licensing, recurring subscription fees for its AI-as-a-Service (AIaaS) platform, and bundled hardware-software sales. The company’s primary business segments focus on AI-assisted diagnostic tools—headlined by its VeriSee DR system for diabetic retinopathy—and smart hospital solutions that integrate AI into clinical workflows. By utilizing proprietary deep learning algorithms trained on extensive clinical datasets, the firm provides automated, high-accuracy screening tools for ophthalmology and radiology. It competes directly with global AI diagnostic firms such as Digital Diagnostics, Eyenuk, and Airdoc. Acer Medical maintains a competitive edge in the Asia-Pacific region by leveraging Acer Group’s global supply chain and securing multi-national regulatory clearances, positioning itself as a key bridge between IT infrastructure and clinical application. The leadership team is headed by Chairman Edward Hsu, a seasoned Acer Group executive with a track record in strategic planning and global market expansion. President Bernice Chen leads the company’s operational and clinical strategy, drawing on her expertise in medical technology commercialization. The founding team consists of engineers and researchers from Acer’s Value Lab, providing the company with a deep technical pedigree in high-performance computing and machine learning. As a majority-owned subsidiary of Acer Inc., the company is backed by the parent group’s substantial R&D resources and institutional capital. The board of directors features prominent industry veterans from the Acer ecosystem, ensuring tight alignment with the group’s broader medical AI initiatives and facilitating partnerships with major hospital systems across Southeast Asia.